Karnon, Jon; Jones, Trefor - In: PharmacoEconomics 21 (2003) 7, pp. 513-525
Background: Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first … comparing letrozole and tamoxifen as first-line hormonal therapies in postmenopausal women diagnosed with advanced breast cancer … in year 2000 values. Results: The baseline results showed that letrozole is a cost-effective alternative to tamoxifen …